Search research articles
Contact Us
Filters
Showing results (1-10 of 50) with videos related to
Page
of 5
Sort By:
Oncolytic Virotherapy
|
March 6, 2018
Potential of oncolytic viruses in the treatment of multiple myeloma
Eric Bartee
Cytokine
|
July 31, 2009
Human cancer cells have specifically lost the ability to induce the synergistic state caused by tumor necrosis factor plus interferon-beta
Eric Bartee, Grant McFadden
Experimental Hematology & Oncology
|
May 27, 2017
In vivo and in situ programming of tumor immunity by combining oncolytics and PD-1 immune checkpoint blockade
Eric Bartee, Zihai Li
Cytokine
|
May 23, 2013
Cytokine synergy: an underappreciated contributor to innate anti-viral immunity
Eric Bartee, Grant McFadden
Molecular Therapy Oncolytics
|
January 1, 2020
Syncytia Formation in Oncolytic Virotherapy
Chase Burton, Eric Bartee
Journal for Immunotherapy of Cancer
|
April 13, 2022
The use of oncolytic virotherapy in the neoadjuvant setting
Raquela J Thomas, Eric Bartee
Molecular Therapy Oncolytics
|
December 18, 2020
Decreasing the Susceptibility of Malignant Cells to Infection Does Not Impact the Overall Efficacy of Myxoma Virus-Based Oncolytic Virotherapy
Erica B Flores, Eric Bartee
Plos Pathogens
|
January 24, 2007
Quantitative membrane proteomics reveals new cellular targets of viral immune modulators
Eric Bartee, Ashley McCormack, Klaus Früh
Current Opinion in Microbiology
|
July 4, 2008
Tumor necrosis factor and interferon: cytokines in harmony
Eric Bartee, Mohamed R Mohamed, Grant McFadden
Oncolytic Virotherapy
|
December 19, 2019
Impact of Induced Syncytia Formation on the Oncolytic Potential of Myxoma Virus
Chase Burton, Mee Y Bartee, Eric Bartee
Page
of 5
Search research articles
Search
Showing results (1-10 of 50) with videos related to
Sort By:
Page
of 5
Oncolytic Virotherapy
|
March 6, 2018
Potential of oncolytic viruses in the treatment of multiple myeloma
Eric Bartee
Cytokine
|
July 31, 2009
Human cancer cells have specifically lost the ability to induce the synergistic state caused by tumor necrosis factor plus interferon-beta
Eric Bartee, Grant McFadden
Experimental Hematology & Oncology
|
May 27, 2017
In vivo and in situ programming of tumor immunity by combining oncolytics and PD-1 immune checkpoint blockade
Eric Bartee, Zihai Li
Cytokine
|
May 23, 2013
Cytokine synergy: an underappreciated contributor to innate anti-viral immunity
Eric Bartee, Grant McFadden
Molecular Therapy Oncolytics
|
January 1, 2020
Syncytia Formation in Oncolytic Virotherapy
Chase Burton, Eric Bartee
Journal for Immunotherapy of Cancer
|
April 13, 2022
The use of oncolytic virotherapy in the neoadjuvant setting
Raquela J Thomas, Eric Bartee
Molecular Therapy Oncolytics
|
December 18, 2020
Decreasing the Susceptibility of Malignant Cells to Infection Does Not Impact the Overall Efficacy of Myxoma Virus-Based Oncolytic Virotherapy
Erica B Flores, Eric Bartee
Plos Pathogens
|
January 24, 2007
Quantitative membrane proteomics reveals new cellular targets of viral immune modulators
Eric Bartee, Ashley McCormack, Klaus Früh
Current Opinion in Microbiology
|
July 4, 2008
Tumor necrosis factor and interferon: cytokines in harmony
Eric Bartee, Mohamed R Mohamed, Grant McFadden
Oncolytic Virotherapy
|
December 19, 2019
Impact of Induced Syncytia Formation on the Oncolytic Potential of Myxoma Virus
Chase Burton, Mee Y Bartee, Eric Bartee
Page
of 5